In clinical research, as in so many other areas of life these days, one must have the wisdom to know the difference between a challenging scenario that calls for a digital solution versus a more practical approach.
It is crucial to improve diversity, equity, and inclusion (DEI) in clinical trials for the health and well-being of everyone.
While oncology has been slower to adopt decentralized clinical trials than other medical specialties, many oncologists realize this type of service could be a game-changer for cancer research and treatments.
Though vaccine developers rapidly adopted decentralized clinical trials during the pandemic, today there is a surprisingly slow uptake of novel technologies across vaccine studies compared to other therapy areas.
There is a real human need contingent upon clinical trials meeting their targeted enrollment, retaining participants, attaining crucial milestones, and resulting in successful outcomes.